BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that research related to its antibody-drug conjugate (ADC) technology was presented at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) being held in Orlando, FL. The presentations highlighted advances being made by the company with its ADC technology and preclinical research on its ADC pipeline, including brentuximab vedotin (SGN-35), SGN-75 and SGN-19A.
